36707-44-5

Basic information

• Product Name: ethyl 4-(acetylamino)-2-(methylsulfanyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylate
• CAS NO: 36707-44-5
• Molecular Formula: C₁₃H₁₄N₄O₄S
• Molecular Weight: 322.3397
• Mol File: 36707-44-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 574.1°C at 760 mmHg
• Flash Point: 301°C
• Density: 1.44g/cm³
• Vapor Pressure: 3.46E-13mmHg at 25°C
• Refractive Index: 1.627
• CAS DataBase Reference: ethyl 4-(acetylamino)-2-(methylsulfanyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(acetylamino)-2-(methylsulfanyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylate(36707-44-5)
• EPA Substance Registry System: ethyl 4-(acetylamino)-2-(methylsulfanyl)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylate(36707-44-5)

Safety Data

• Hazardous Substances Data: 36707-44-5(Hazardous Substances Data)

Upstream product

• 41343-58-2 diethyl 2-ethoxymaleate 
• 36707-42-3 diethyl 2-((6-amino-2-(methylthio)pyrimidin-4-ylamino)methylene)malonate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 1005-39-6 4,6-diamino-2-methylthiopyrimidine 
• 36707-43-4 [(6-acetylamino-2-methylsulfanyl-pyrimidin-4-ylamino)-methylene]-malonic acid diethyl ester 

Relevant articles and documents

COMPOUNDS USEFUL AS AKT/PKB MODULATORS AND USES THEREOF

Compounds, and pharmaceutical compositions, and formulations thereof, are disclosed that have formula (I): where R1a, R1b, R1c, R2, R3, R6a, R6b, R6c, R7, and R8 are as defined herein. The compounds, pharmaceutical compositions, and pharmaceutical formulations thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and others. The manufacturing and analytical methods for LD- 101 are also disclosed.

NOVEL COMPOSITIONS AND METHODS OF USE

Described herein are novel enzyme inhibitors. In some embodiments the enzyme inhibitors are integrase inhibitors, particularly HIV integrase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV integrase as a method of treating or preventing HIV, AIDS or related disorders.